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Background: Coding Region Determinant –
Binding Protein (CRD-BP) interacts physically 
with oncogenic mRNAs. 
Results: Point mutation in the K-homology (KH) 
domains of CRD-BP abolishes its RNA-binding 
ability. 
Conclusion: Two KH domains of CRD-BP are 
required for efficient binding to oncogenic 
mRNAs, and for granule formation in zebrafish 
embryos. 
Significance: Learning how the KH domains 
interact with mRNAs is crucial for understanding 
oncogenic function of CRD-BP. 
 
ABSTRACT 
The ability of its four heterogeneous 
nuclear ribonucleoprotein-K-homology (KH) 
domains to physically associate with oncogenic 
mRNAs is a major criterion for the function of 
Coding Region Determinant-Binding Protein 
(CRD-BP). However, the particular RNA 
binding role of each of the KH domains 
remains largely unresolved. Here, we mutated 
the first glycine to an aspartate in the 
universally conserved Glycine-X-X-Glycine 
(GXXG) motif of the KH domain as an 
approach to investigate their role. Our results 
show that mutation of a single GXXG motif 
generally had no effect on binding but the 
mutation in any two KH domains, with the 
exception of the combination of KH3 and KH4 
domains, completely abrogated RNA-binding in 
vitro and significantly retarded granule 
formation in zebrafish embryos, suggesting that 
any combination of at least two KH domains 
cooperate in tandem to bind RNA efficiently. 
Interestingly, we found that any single point 
mutation in one of the four KH domains 
significantly impacted CRD-BP binding to 
mRNAs in HeLa cells, suggesting that the 
dynamics of CRD-BP-mRNA interaction vary 
over time in vivo. Furthermore, our results 
suggest that different mRNAs bind 
preferentially to distinct CRD-BP KH domains. 
The novel insights revealed in this study have 
important implications on the understanding of 
the oncogenic mechanism of CRD-BP a well as 
in the future design of inhibitors against CRD-
BP function. 
 
Coding region determinant-binding protein 
(CRD-BP; mouse), also known as IMP1 (human), 
belongs to a highly conserved family of RNA-
binding proteins called VICKZ (Vg1 RBP/Vera, 
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IMP-1,2,3, CRD-BP, KOC, ZBP-1) (1,2). Other 
orthologous or paralogous members include IMP2 
(human), IMP3 (human), ZBP1 (chicken), and 
Vg1-RBP/Vera (Xenopus). All members of 
VICKZ have two N-terminal RNA recognition 
motifs (RRM) followed by four C-terminal 
heterogeneous nuclear Ribonucleoproteins-K-
homology (KH) domains, and have been 
implicated in the post-transcriptional regulation of 
a number of different mRNAs (1,2).   
CRD-BP was first discovered due to its ability 
to physically associate with a specific coding 
region of c-myc mRNA called the coding region 
determinant (3,4), and its ability to influence c-
myc mRNA stability in a cell-free model system 
(5). Several subsequent studies have provided in-
vivo evidence for the role of CRD-BP in 
controlling c-myc mRNA half-life (6-9). In 
addition to c-myc, CRD-BP also has high affinity 
for a number of mRNAs whose gene products 
have been implicated in cancer, which include 
mRNAs for βTrCP1 (8), CD44 (10), IGF-II (11), 
GLI1 (12), β-catenin (13), K-Ras (14), MAPK4 
(15), MITF (16) and MDR1 (17). The oncogenic 
role of CRD-BP is further exemplified by the 
following two observations: (i) over-expression of 
CRD-BP in many types of human cancers (2), and 
(ii) mice genetically engineered to over-produce 
CRD-BP in mammary glands developed 
mammary adenocarcinoma (18). Although the 
exact oncogenic function of CRD-BP is still 
unclear, many studies using cell lines have 
demonstrated that its ability to physically interact 
with target mRNAs is at least one major 
contributing factor.  For instance, it was shown 
that CRD-BP binds with high affinity to several 
regions at the 3’untranslated region (UTR) of 
CD44 mRNA  to stabilize it, leading to cell 
adhesion, cytoplasmic spreading and invadopodia 
formation (10). CRD-BP binds to the coding 
region of βTrCP1 mRNA and over-expression of 
CRD-BP led to the stabilization of βTrCP1 mRNA 
and elevation of βTrCP1 expression levels in 
colorectal cancer cells (8). CRD-BP has recently 
been shown to bind to the coding region of β–
catenin (13) and GLI1 mRNAs (12) to stabilize the 
transcripts, providing further evidence for the role 
of CRD-BP in the Wnt/ β–catenin signaling 
pathway. CRD-BP also binds to the coding region 
and 3’ UTR of K-Ras mRNA and its 
overexpression led to increases in K-Ras 
expression as well as colon cancer cell 
proliferation (14). Furthermore, the 3’UTR of 
MITF mRNA is also a binding site for CRD-BP 
and such an interaction is shown to be critical for 
protecting the MITF transcript from degradation 
by miR-340, a mechanism believed to be 
important in melanocytes and malignant 
melanoma (16). 
To date, most if not all of our understanding 
on the structure and function of CRD-BP have 
been derived from studies on its paralogs. Deletion 
analysis studies of the human (IMP1), frog 
(Vg1RBP), and chicken (ZBP1) paralogs of CRD-
BP have all concluded that the two RRMs are not 
important for RNA binding (19-21). However, 
there are some conflicting results regarding the 
significance of each KH domain with respect to 
their interaction with RNA. For instance, while the 
KH3&4 di-domain of ZBP1 appears to be 
sufficient to bind to its RNA substrate, the 54-nt 
zipcode β–actin RNA (21), this was not the case 
for IMP1 and Vg1RBP. Unlike the full-length and 
KH1-4 recombinant proteins, the KH3&4 
didomain of IMP1 showed no affinity for the 173-
nt H19 RNA (20). Similarly, the recombinant 
protein containing only the KH3&4 di-domain of 
Vg1RBP exhibited more than a 10-fold decrease 
in affinity for VLE RNA when compared to the 
wild-type protein (19). The crystal structure of the 
KH3&4 di-domain of IMP1 has recently been 
determined, and it has been proposed that RNA 
looping induced by IMP1 binding is the 
mechanism whereby IMP1 provides specific 
recognition for its RNA substrates (21). Using 
nuclear magnetic resonance spectroscopy, it was 
demonstrated that the C-terminal KH3 and KH4 
domains can recognize a bipartite RNA sequence, 
with KH4 binding to a 5’ CGGAC element and 
KH3 binding to a 5’ C/A-CA-C/U element (22). In 
deciphering the role of the RNA-binding domains 
of CRD-BP paralogs, all the above mentioned 
studies have utilized isolated domains or employed 
deletion variants and hence it is still unclear to 
what extent each KH domain plays in the context 
of the entire CRD-BP protein in binding to RNA. 
The minimal eukaryotic (type 1) KH domain 
is characterized by a 1122 topology, with the 
maxi KH domain containing an extra ’’ at its C-
terminus. Typically, the KH domain fold consists 
of three anti-parallel -strands in the order 1, ’ 
and 2 creating the core of the domain. The core β 
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sheet is framed on three sides by the -helices, 
forming the outer face of the domain. The RNA 
binding platform is located on the outer, solvent 
exposed face of the 12 region, where the RNA 
substrate is positioned between two flexible loops 
(23).  Essential to the KH domain RNA binding 
platform is a strictly conserved GXXG motif, 
located within a flexible loop between 1 and 2 
(23). This GXXG motif, in concert with a variable 
loop located between 2 and ’, functions to clamp 
an RNA substrate in place upon binding. It is 
thought that the glycine residues in the GXXG 
motif are essential due to their conformational 
flexibility and small steric size (24). 
Correspondingly, the RNA binding function of the 
KH domains of NusA, GLD-1, Sam68, and 
hnRNP K were all severely impeded upon 
mutating the first glycine in the GXXG motif to an 
aspartate (24-27). In fact, a recent study showed 
the feasibility of double mutating the GXXG loop, 
namely from GXXG to GDDG, in the KH domain 
of the RNA-binding protein KSRP and the KH3 
and KH4 domains of IMP1, as an effective tool for 
the investigation of the nucleic acid-binding 
function of individual KH domains (28). 
In the present study, we use site-directed 
mutagenesis to mutate the first Gly residue in each 
of the GXXG motifs in the KH domains of CRD-
BP as an approach to understand to what degree 
each of the four domains are involved in binding 
to RNA substrates in vitro and in cells. We show 
that, with the exception of KH3-4, mutations in 
any two GXXG motifs in the four KH domains 
leads to a complete abrogation of CRD-BP 
binding to c-myc and CD44 RNAs in vitro. We 
also show that these in vitro RNA-binding profiles 
correlate with CRD-BP granule formation in intact 
zebrafish (Danio rerio) embryos. However, we 
find that even a single GXXG point mutation in 
each KH domain individually can lead to a 
significant decrease in the amount of c-myc and 
CD44 mRNAs associated with FLAG-CRD-BP in 
HeLa cells. Taken together, our results reveal 
important insights into how CRD-BP physically 
associates with its RNA binding partners. 
 
EXPERIMENTAL PROCEDURES 
Plasmid construction - The plasmids pET28b(+)-
CRD-BP and pcDNA-CRD-BP-FLAG containing 
mouse CRD-BP cDNA were generous gifts from 
Dr. Jeffrey Ross, University of Wisconsin.  The 
pET28b(+)-CRD-BP was used to generate 
recombinant WT CRD-BP while the pcDNA-
CRD-BP-FLAG was used to over-express FLAG-
CRD-BP in HeLa cells. For the generation of 
various KH point mutation variants, we used the 
PCR-based site-directed mutagenesis method 
employing pET28b(+)-CRD-BP and pcDNA-
CRD-BP-FLAG as templates. To generate the 
single KH variants, the following primer pairs 
were used. KH1: forward primer 5’-GGCGCT 
ATCATTGACAAGGAGGGTGCC-3', reverse 
primer 5'-GGCACCCTCCTTGTCAATGAT 
AGCGCC-3'; KH2: forward primer 5'-GGGCGA 
CTCATTGACAAGGAAGGGCGG-3', reverse 
primer 5'-CCGCCCTTCCTTGTCAATGAG 
TCGCCC-3'; KH3: forward primer 5'-GGCGCC 
ATCATTGACAAGAAGGGCCAG-3', reverse 
primer 5'-CTGGCCCTTCTTGTCAATGAT GGC 
GCC-3'; KH4: forward primer 5'-CCGC GTC 
ATCGACAAAGGCGGCAAAAC-3', reverse 
primer 5'-GTTTTGCCGCCTTTGTCGATGAC 
GCGG-3'. Bases altered from the CRD-BP cDNA 
are shown in bold and the targeted codons are 
underlined. KH variants containing a point 
mutation at the GXXG motif in two KH domains 
were sequentially generated. For instance, to 
generate the KH1-2 variant, the KH1 plasmid was 
used as a template and the primer set to point 
mutate the GXXG motif in the KH2 domain were 
used in PCR-based site-directed mutagenesis. 
For the generation of the WT CRD-BP-EGFP-
pSp64TNE plasmid, the open reading frame of 
CRD-BP was amplified by PCR using the plasmid 
pcDNA-CRD-BP-FLAG as a template and the 
following primer pairs: CRD-BP-Kpn1-F (5’- 
ACCAGGTACCATGAACAAGCTTTACATCG
GCA-3’) and CRD-BP-Age1-R (5’- 
ACCAACCGGTAACTTCCTCCGAGCCTGGGC
CA-3’). The amplified fragment was then inserted 
into the KpnI and AgeI restriction sites of the 
EGFP-pSp64TNE plasmid. Similarly, for the 
generation of the EGFP-pSp64TNE KH point 
mutation variants, the open reading frame of the 
KH point mutation variants were amplified using 
the appropriate pcDNA-CRD-BP-FLAG KH 
variants as templates and CRD-BP-Kpn1-F and 
CRD-BP-Age1-R primers, and the PCR amplified 
fragments were inserted into the same sites of 
EGFP-pSp64TNE as described above. For the 
generation of truncated CRD-BP in EGFP-
pSp64TNE plasmids, the following primer pairs 
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were used: RRM1&2 (forward primer CRD-BP-
Kpn1-F, reverse primer  
5’ACCAACCGGTAACCCTGCTGCCACGGGC
GACCCTT-3’); KH1 to 4 (CRD-BP-KH1-Kpn1-F 
5’ACCAGGTACCATGATCCCTCTCCGGCTCC
TGGT-3’, reverse primer CRD-BP-Age1-R); KH1 
(CRD-BP-KH1-Kpn1-F, CRD-BP-KH1-Age1-R 
5’ACCAACCGGTAACAAGATCATCTTGCAC
GCGGA-3’); KH2 (CRD-BP-KH2-Kpn1-F   
5’CCAGGTACCATGCTGAAGATCCTGGCTC
ATAAC-3’, CRD-BP-KH2-Age1-R 5’ 
ACCAACCGGTAACTCTCGAACTTTCTTCAT
GAT-3’); KH3 (CRD-BP-KH3-Kpn1-F 
5’ACCAGGTACCATGGTACAAGTGTTCAT-
3’, CRD-BP-KH3-Age1-R 5’ 
ACCAACCGGTGTAGCCTCTGGGGGTCCAG
T-3’); KH4 (CRD-BP-KH4-Kpn1-F 5’ 
ACCAGGTACCATGAAGCTAGAGACCCACA
TACGG-3’, CRD-BP-Age1-R); KH1&2 (CRD-
BP-KH1-Kpn1-F, CRD-BP-Age1-R); KH2&3 
(CRD-BP-KH2-Kpn1-F, CRD-BP-KH3-Age1-R); 
KH3&4 (forward primer 
5’ACCAGGTACCATGGCTCCCTATAGCTCCT
TCATGCA-3’, CRD-BP-Age1-R). Two sub-
cloning steps were used to generate the di-KH 
domains KH1&3, KH1&4, and KH2&4 EGFP 
constructs. For generating KH1&3-EGFP-
pSp64TNE, KH1 was amplified by PCR and 
subcloned into the Kpn1 site at the 5’ end of KH3-
EGFP-pSp64TNE construct.  The same fragment 
was subcloned into the 5’end of KH4-EGFP-
pSp64TNE construct to generate KH1&4-EGFP-
pSp64TNE.  For generating KH2&4-EGFP-
pSp64TNE, KH2 was amplified by PCR and 
subcloned into the 5’ end of KH4-EGFP-
pSp64TNE.   
All of the above generated constructs were 
verified by DNA sequencing performed by 
Macrogen (Seoul, Korea). 
Generation and purification of recombinant 
CRD-BP and its variants - Recombinant CRD-BP 
was purified from Escherichia coli BL21 (DE3) 
using a 1 mL bed volume of nickel-NTA 
(QIAGEN) column under denaturing conditions. 
Proteins eluted from the column at pH 5.4 were 
subjected to three steps of dialysis. The first step 
was for 24 hours in pH 7.4 buffer containing 200 
mM NaCl, 20 mM Tris-HCl, 1 mM reduced 
glutathione, 0.1 mM oxidized glutathione, 10% 
(v/v) glycerol, 2 M urea, and 0.01% (v/v) Triton 
X-100. The protein was then dialyzed twice each 
for 2 hours in the same buffer as above but without 
urea and the glutathiones. Following dialysis, 
samples were centrifuged at 13,200 rpm for 30 
min to remove any precipitated proteins. The 
purified protein solutions were quantified and 
analyzed for purity using Coomassie brilliant blue-
stained 12% SDS-PAGE. 
Radiolabelled in vitro transcription - Plasmid 
pUC19-CRDmyc-1705-1886 was used to amplify 
DNA template for use to synthesize internally 
radiolabeled 182 nts c-myc CRD RNA.  The PCR 
primers used to amplify c-myc DNA 
corresponding to nts 1705-1886 are:   forward 
primer, 
GGATCCTAATACGACTCACTATAGGACCA
GATCCCGGAGTTGG; reverse primer, 
TAGCTGTTCAAGTTTGTG. The T7 RNA 
promoter sequences are underlined. The plasmid 
pCYPAC2-CD44 which contains the last CD44 
exon was a gift from Dr. Finn C. Nielsen 
(University of Copenhagen, Denmark), and was 
used as template for PCR amplification. The PCR 
primers that were used to amplify the CD44 DNA 
nts 2862-3055, corresponding to the 3΄UTR of 
CD44 mRNA are:   forward primer, 
GGATCCTAATACGACTCACTATAGGAAATT
AGGGCCCAATTAA; reverse primer, 
AAATTTCCTCCCAGGGAC. PCR amplified 
DNA templates were used directly for in vitro 
transcription by T7 RNA polymerase. One µg of 
DNA template was incubated for 1 hour at 37°C in 
a 20-µl reaction containing 1 x transcription buffer 
(Promega, Madison, Wisconsin), 10 mM 
dithiothreitol, 1 unit RNasin (Promega), 0.5 mM 
ATP, 0.5 mM CTP, 0.5 mM GTP, 12.5 µM UTP, 
1.5 units T7 RNA polymerase (Promega, Madison, 
WI), and 40 µCi [α-32P] UTP (3000 Ci/mmol). 
Following incubation, 3 units RNase-free DNase I 
(Promega) were added and the reaction was 
further incubated for 10 minutes at 37°C. Upon 
addition of 10 µl Stopping dye (9 M urea, 0.01% 
bromophenol blue, 0.01% xylene cyanole FF, 
0.01% phenol), the entire sample was 
electrophoresed on a 8% polyacrylamide/7M urea 
gel and the band containing internally-radiolabeled 
RNA was excised and eluted with elution buffer 
(10 mM Tris-HCl pH 7.5, 0.1M NaCl, 1 mM 
EDTA, 0.01% SDS) at 45
0
C for 6 hours. The 
purified radiolabeled RNA was then 
phenol/chloroform extracted followed by ethanol 
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precipitation. Specific activity of the RNA was 
then determined by scintillation counting.  
Electrophoretic mobility shift assay - The 
electrophoretic mobility shift assay (EMSA) 
binding buffer (5 mM Tris-Cl pH 7.4, 2.5 mM 
EDTA pH 8.0, 2 mM DTT, 5% glycerol, 0.1 
mg/ml bovine serum albumin, 0.5 mg/ml yeast 
tRNA, 5 units RNasin) (17) was prepared on ice 
prior to each experiment. In order to facilitate 
RNA denaturation and renaturation, the [
32
P]-
labeled RNA sample was heated to 55°C for 5 min 
and cooled to room temperature before adding the 
EMSA binding buffer and the appropriate amount 
of purified recombinant CRD-BP to a final volume 
of 20-μL. Reactions were incubated at 37°C for 10 
minutes and transferred to ice for 5 min. The 
reaction was again incubated at 37°C for 10 
minutes and transferred to ice for an additional 5 
min. A total of 2 μL EMSA loading dye (250 mM 
Tris-Cl pH 7.4, 0.2% bromophenol blue, 0.2% 
xylene cyanol, 40% sucrose) was added to each 
reaction and 15 μL of the EMSA reaction was 
loaded onto a 4% native polyacrylamide gel and 
resolved at 25 mA for 60 minutes. Following 
electrophoresis, the gel was exposed overnight at -
80°C and subjected to autoradiography using the 
Cyclone PhosphorImager and Optiquant Software.   
EMSA saturation binding experiments were 
carried out as described above and the dissociation 
constant (Kd) for the CRD-BP-RNA interaction 
was determined using the Hill equation. The 
saturation binding data was analyzed by 
densitometry of the autoradiograph using the 
Cyclone Storage Phosphor-System and Optiquant 
software. For each reaction, the total activity in 
each lane was determined; this involved summing 
the total activity in bound complexes with the total 
activity present in the unbound fraction. The 
percentage of bound RNA and the protein 
concentration (nM) were inserted into the Hill 
equation and the results were expressed 
graphically. 
Cell culture, transfection and immuno-
precipitation - HeLa human cervical cancer cells 
purchased from ATCC were cultured in Minimum 
Essential Media supplemented with 10% fetal 
bovine serum at 37°C in 5% CO2. The day before 
transfection, 10 x 10
4
 cells/mL were plated onto 
100 mm dishes. Transient transfection of 10 µg of 
pcDNA-CRD-BP-FLAG plasmids was carried out 
using Lipofectamine 2000 reagent (Invitrogen, 
Burlington, ON) as according to the 
manufacturer’s instructions. As a negative control, 
cells were transfected with the plasmid vector 
pcDNA-FLAG. Forty eight hours after 
transfection, cells were lysed with 1 mL Total Cell 
Lysis (TCL) buffer (50 mM Tris-Cl pH 7.4, 150 
mM NaCl, 1 mM EDTA, 0.1% Triton X-100) 
supplemented with 1 mM vanadyl ribonucleoside, 
0.5 mM DTT, 0.05 units RNasin, and protease 
inhibitor tablet (Roche Diagnostics, Laval, 
Quebec). After 5 minutes on ice, lysed cells were 
aspirated using a 25.5 gauge needle five times to 
break the nuclei. After a 30 minute incubation on 
ice, the cell lysate was centrifuged at 14,000 rpm 
for 10 minutes. The collected supernatant was 
subjected to preclearing by incubating with 50 µL 
equilibrated-protein-G agarose beads (50% slurry) 
at 4°C for at least 1 hour. The resin was spun 
down at 3000xg for 1 minute and the lysate was 
collected. The pre-clearing step was repeated once 
after which the pre-cleared lysate was added to 5 
µL anti-FLAG antibody (#F1804, Sigma-Aldrich, 
Oakville, Ontario) and mixed overnight at 4°C. 
Protein G-agarose beads were then added to the 
antibody-lysate mixture and mixed for four hours 
at 4°C to capture the FLAG antibody. The agarose 
beads were then washed four times with TCL 
buffer followed by five washes with TCL buffer 
containing 1 M urea. Following the fourth wash 
with TCL buffer containing urea, 50% of the 
agarose beads were collected and spun down at 
3000xg for 1 minute followed by resuspension in 
16 µL of water for Western blot analysis. The 
remaining 50% of the agarose beads was subjected 
to a final wash followed by resuspension in 100-
µL TCL buffer containing 0.3 mg/mL proteinase 
K and 0.1% SDS. The sample was then incubated 
at 50°C for 30 minutes.  Following the incubation, 
RNAs physically associated with the resin were 
extracted by the phenol-chloroform-isoamyl 
alcohol method and quantified using a Nanodrop 
Spectrometer (Wilmington, Delaware). One µg of 
RNA from each treatment group was treated with 
DNase (DNA-free
TM
 kit, Ambion) before 
subjecting the sample for cDNA synthesis and 
quantitative real-time PCR as described below. 
We also used an equal volume of RNA samples 
for normalization purposes and found no 
differences in the quantitative real-time PCR 
results. 
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Western blot analysis - Protein samples were 
separated using a 12.5% polyacrylamide/SDS 
Lammeli gel system, transferred to a nitrocellulose 
membrane, and incubated against anti-FLAG 
antibody (#200472-21, Stratagene, La Jolla, 
California). PageRuler Plus Prestained Protein 
Ladder (Thermo Fisher Scientific, Rockford, 
Illinois) was used to identify the molecular weight 
of FLAG-CRD-BP bands. The FLAG-CRD-BP 
bands were detected using the standard 
chemiluminescent technique, and visualized using 
Alpha Innotech FluorChem 5500. The 
AlphaEaseFC software program was used to 
assign an Integrated Density Value to each of the 
FLAG-CRD-BP bands. 
Quantitative real-time PCR - The first strand 
cDNA synthesis was performed using iScript 
cDNA Synthesis kit (QBio-Rad) on 1 μg of total 
RNA or equi-volume of RNA samples, and the 
qPCR was performed using iQ SYBR Green 
Supermix (Bio-Rad) on an iQ5 Multicolor Real-
Time PCR Detection System (Bio-Rad). The PCR 
primers synthesized by IDT Inc. were: CD44 
forward primer, 5’-CAT CAG TCA CAG ACC 
TGC CCA ATG C-3’, and CD44 reverse primer, 
5’-ATG TAA CCT CCT GAA GTG CTG CTC C-
3’; c-myc forward primer, 5’-ACG AAA CTT 
TGC CCA TAG CA-3’, and c-myc reverse primer, 
5’ GCA AGG AGA GCC TTT CAG AG-3’; β-
actin forward primer, 5’-TTG CCG ACA GGA 
TGC AGA AGG A-3’, and β-actin reverse primer, 
5’-AGG TGG ACA GCG AGG CCA GGA T-3’. 
The cycling protocol consisted of 95°C for 3 min 
and 40 cycles of denaturation at 95°C for 10 s, 
annealing at 52°C for 30 s. To confirm 
amplification specificity, we performed a melting 
curve analysis at the end of each cycling. Each 
sample was run in triplicate, and the data were 
analyzed using iQ5 optical system software. Serial 
dilutions were carried out for each total RNA 
sample and reverse-transcribed under the above-
mentioned conditions for each primer set to ensure 
amplification with efficiencies near 100%. The CT 
values for target genes (CD44, c-myc, and β-actin) 
were then used in the comparative CT method or 
commonly known as the 2
-CT
 method (29) to 
determine the expression level of the target gene in 
pcDNA CRD-BP-FLAG-transfected cells (WT 
and variants) and pcDNA-FLAG-transfected cells.  
To ensure that there was no genomic DNA 
contamination in the cDNA samples used for the 
IP qPCR experiments, no-Reverse Transcriptase 
(no-RT) controls were used in each of the cDNA 
synthesis reactions. These samples were subjected 
to the same RT-qPCR reactions as the test samples 
and genomic DNA contamination was assessed.  
Data collected from four biological replicates 
were pooled and one-way ANOVA statistical 
analysis was performed to compare mRNA levels 
in the variants to the wild-type CRD-BP. 
Circular dichroism analysis - Circular 
dichroism (CD) spectra of all CRD-BP variants 
were attained using a Jasco J-815 CD 
spectrometer. Temperature during scanning was 
maintained at 25°C using a Peltier temperature-
control device and proteins sampled in a 0.1 cm 
path-length quartz cell. CD measurements were 
recorded using wavelength scans of 195-240 nm, 
with all protein sample concentrations between 1 
and 2 μM resuspended in 20 mM Tris buffer pH 
7.4, 10% glycerol, 200 mM NaCl. Measurement 
parameters were standard resolution 100 mdeg, 
bandwidth 1 nm, D.I.T. 2 seconds, scan rate 100 
nm/min, and accumulation of 8 scans. Data 
analysis: Secondary structure estimates were de-
convoluted using the K2D3 neural networking 
algorithm (30). 
Embryo collection - The AB strain of 
zebrafish (Danio rerio) (from the Zebrafish 
International Resource Centre; University of 
Oregon, Eugene, OR, USA) were maintained 
according to standard laboratory practices and all 
experiments were approved by the HKUST 
Institutional Animal Care and Use Committee. 
Fishes were maintained on a 14 hour light/10 hour 
dark cycle to stimulate spawning, and their 
fertilized eggs were collected as described 
previously (31). Embryos were maintained in 30% 
Danieau’s solution (17.4 mM NaCl, 0.21 mM 
KCl, 0.18 mM Ca(NO3)2, 0.12 mM MgSO4.7H2O, 
1.5 mM Hepes, pH 7.2) at ~28.5°C throughout 
development and during all experiments. 
Transient expression of EGFP-CRD-BP, 
microinjection, microscopy and image acquisition 
and analysis of zebrafish embryos - For mRNA 
production, the WT CRD-BP-EGFP and various 
mutant CRD-BP-EGFP plasmids were linearized 
and transcribed using an mMESSAGE 
mMACHINE
TM
 (Ambion) in vitro transcription 
kit. For the transient expression of EGFP-CRD-BP 
fusion proteins, zebrafish embryos were injected 
with mRNA at the one-cell stage, unless otherwise 
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stated. For acquisition of live images, embryos 
were immobilized in grooves made in a 1% 
agarose gel and bathed in 30% Danieau’s solution 
(31). Most images were acquired using a Nikon 
C1 confocal system mounted on a Nikon 90i 
upright microscope using Nikon Fluor 40x/0.80 W 
or 60x/1.00W water immersion objectives and a 
pinhole size of 60 µm. Alternatively, some images 
were acquired using a Carl Zeiss LSM 780 system 
configured on an inverted Observer Z1 microscope 
and a 40x oil immersion objective.  All images 
shown are single confocal sections of 512 x 512 
pixels.  Subsequent color and contrast 
enhancement was done using Corel 
PHOTOPAINT 11.  Granules were quantified in 
all images using the “Analyze Particles” function 
in ImageJ software with a filter to detect granule 
size of 6-200 pixels
2
 and circularity of 0.40-1.00.  
The number of granule is expressed per cell and 
the number of cells in each image was counted 
manually.   
 
RESULTS 
Point mutations in the GXXG motif of two KH 
domains generally abolish the ability of CRD-BP 
to bind c-myc and CD44 RNAs in vitro - To assess 
the importance of each KH domain in binding to 
RNA in the context of the full-length protein, we 
generated single point mutations within the GXXG 
motif of each individual KH domain. We mutated 
the first glycine of each GXXG motif to an 
aspartate as a way to remove the function of each 
individual KH domain (Fig. 1A). For simplicity, 
we have used the following abbreviation to name 
the point mutations as KH variants. For instance, 
KH1 variant has the point mutation in the GXXG 
motif within the KH1 domain whereas the KH2 
variant has the point mutation in the GXXG motif 
within the KH2 domain. The KH1-2 variant has 
the point mutations at the GXXG motifs of both 
the KH1 and KH2 domains, whereas, the KH3-4 
variant has the point mutations in the GXXG 
motifs of the KH3 and KH4 domains, and so on 
(Fig. 1A). As negative controls, we also generated 
four CRD-BP variants with point mutations that 
are not expected to affect the RNA-binding ability.  
CRD-BP variants with point mutations in the 
RRM1 (Y5A) or RRM2 domain (Q84A) were 
selected (Fig.1A). The E445D and D526E variants 
containing a point mutation in the variable loop 
located between β2 and β3 in KH3 and KH4 
domains (21) respectively, were also generated 
(Fig. 1A). The recombinant mouse wild-type (WT) 
CRD-BP and mutant proteins were purified to 
~95% homogeneity (Fig. 1B).   
Using electrophoretic mobility gel-shift 
assays, we compared the binding profiles of the 
WT CRD-BP and its variants on two high affinity 
target RNAs: the 182 nts 
32
P-labeled c-myc RNA 
(nts 1705-1886) (Fig. 2) and 194 nts 
32
P-labeled 
CD44 RNA (nts 2862-3055) (10, 32) (Fig. 3). Fig. 
2A shows representative results from gel-shift 
assays for binding the 182 nts c-myc RNA. It is 
clear that the KH1-2, KH1-3, KH1-4, KH2-3, and 
KH2-4 variants had completely abolished ability 
to bind the c-myc RNA. In contrast, KH3-4 and 
the single point mutation variants KH1, KH2, 
KH3, and KH4, all exhibited binding to c-myc 
RNA (Fig. 2A). Results from three biological 
replicates were pooled and the saturation-binding 
data were fitted to the Hill equation and expressed 
graphically to determine the dissociation constant 
(Kd) and Hill coefficient. A summary, showing Kd 
for the interaction of each of the recombinant 
protein variants with c-myc RNA is shown in 
Table 1, and the results are plotted for direct 
comparison in Fig. 2B. As shown in the 
quantitative data, KH3-4 and KH1 displayed 
slightly higher Kd values as compared to the WT 
CRD-BP, whereas KH2, KH3, KH4, Y5A, Q84A, 
D526E, and E445D, all displayed binding profiles 
that are comparable to the WT CRD-BP. On the 
other hand, KH1-2, KH1-3, KH1-4, KH2-3 and 
KH2-4 displayed significantly reduced or no 
binding to c-myc RNA based on data from three 
biological replicates (Fig. 2B). 
Fig. 3A shows representative results from gel-
shift assays for binding of the CRD-BP variants to 
the 194 nts CD44 RNA. From the results, it is 
clear that the KH1-2, KH1-3, KH1-4, KH2-3, and 
KH2-4 mutants are unable to bind CD44 RNA. In 
contrast, the Y5A, D526E, KH1, KH2, KH3, and 
KH3-4 mutants all displayed the ability to bind 
CD44 RNA. The slightly different shift in the 
complex for KH3-4 as compared to the WT was 
because the two groups of samples were 
electrophoresed on different gels. KH4 appeared 
to bind CD44 RNA very weakly (Fig. 3A), and 
hence the saturation-binding curve as well as the 
Kd could not be obtained. A summary of the Kd 
values for the WT and mutant CRD-BP proteins 
that were obtained from the saturation-binding 
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data is shown in Table 1 and plotted for direct 
comparison in Fig. 3B. Both the Y5A and D526E 
mutants displayed slightly lower Kd values 
indicating their higher affinity for CD44 RNA 
while KH1, KH2 and KH3 had slightly higher Kd 
values indicating their lower affinity for CD44 
RNA. Results from three biological replicates 
confirmed that the KH4, KH1-2, KH1-3, KH1-4, 
KH2-3 and KH2-4 mutants have significantly 
reduced or no binding to CRD-BP (Fig. 3B). 
In summary, we found that with the exception 
of KH3-4, simultaneous point mutation of the 
GXXG motif in two KH domains generally 
abolishes the ability of CRD-BP to bind c-myc and 
CD44 RNAs. We also found that while the KH4 
variant has high affinity for c-myc RNA, it was 
very inefficient in binding CD44 RNA. Similarly, 
the KH2 and KH3 variants have higher Kd values 
than that of the WT CRD-BP in binding CD44 
RNA, but not for binding c-myc RNA. 
No global secondary structure changes occur 
in CRD-BP upon point mutation of the KH domain 
GXXG motif - To determine if there were major 
global changes in the secondary structure upon 
point mutation at the GXXG motifs, we performed 
circular dichroism spectroscopy on the WT CRD-
BP as well as the KH domain mutants in the 
wavelength range of 195-240 nm. The ‘w-shaped’ 
spectrum with a clear trough close to 208 nm and a 
less distinctive trough near 222 nm are indicative 
of the presence of α–helical structure. The CD 
spectrum of the entire CRD-BP protein is 
remarkably similar to that generated for the 
recombinant KH3&4 di-domain of ZBP1 (22). All 
of the point mutation variants exhibited CD 
spectra that are very similar, if not identical, to 
that of the WT CRD-BP (data not shown). We also 
estimated the percentages of α–helix and β–sheet 
present in the WT CRD-BP and the KH variants 
and found no significant differences (data not 
shown). Hence, we conclude that point mutations 
in the GXXG motifs of the KH domains do not 
alter the global secondary structure of CRD-BP. 
CRD-BP granule formation in zebrafish 
embryos is dependent on newly transcribed zygotic 
RNAs - Next, we were interested in determining 
whether our findings that the RNA-binding ability 
of CRD-BP is abrogated upon introducing the 
GXXG motif point mutations in any two KH 
domains were translatable to an in vivo cellular 
system. Since the ability of IMP1 to bind RNA has 
been shown to be a pre-requisite for the formation 
of IMP granules in NIH 3T3 cells (20), we decided 
to use CRD-BP granule formation as our first 
cellular system. We turned to the zebrafish embryo 
as an in vivo model because the optical clarity of 
this system is microscopically superior and thus 
facilitates the rapid identification of CRD-BP 
granules.  Furthermore, CRD-BP granule 
formation in zebrafish embryos is likely to be 
visible within a few hours upon translation, 
allowing visualization of the protein-RNA 
interaction at early time points which is not 
possible using a regular mammalian transfection 
system. 
We first performed characterization 
experiments to explore and understand mouse 
CRD-BP granule formation in intact zebrafish 
embryos. We found that during the first 3 hours in 
the absence of zygotic bio-molecules, CRD-BP 
granules were absent (Fig. 4Ai). However, at 4 
hours post-fertilization (hpf), CRD-BP granules 
were clearly visible (Fig. 4Aii), suggesting that 
CRD-BP granule formation strictly coincides with 
the mid-blastula transition that indicates a switch 
from maternal to zygotic transformation. We also 
assessed granule formation upon injection with the 
human IMP1-EGFP mRNA. As shown in Figs. 
4Aii and iii, the granule formation by the mouse 
CRD-BP is remarkably similar to the human 
IMP1, indicating that granule formation by the two 
orthologs is very similar in zebrafish embryos. To 
determine if CRD-BP granule formation is 
dependent on newly transcribed RNA, we injected 
the transcriptional inhibitor Actinomycin D 
immediately after CRD-BP-EGFP mRNA 
injection. We found that Actinomycin D 
completely abolished the formation of CRD-BP 
granules (Fig. 4Bii), confirming that expression of 
zygotic genes is required for CRD-BP granule 
formation. To determine whether zygotic RNAs or 
proteins are important for granule formation, we 
injected the protein synthesis inhibitor 
cycloheximide either immediately after injection 
of CRD-BP-EGFP mRNA to inhibit total protein 
synthesis, or at the 16-cell stage to allow 
expression of CRD-BP-EGFP before inhibition of 
zygotic protein synthesis. We found that the 
expression of CRD-BP-EGFP was inhibited by 
cycloheximide treatment if given immediately 
after mRNA injection (Fig. 4Biii). However, if 
cycloheximide was given at a later stage to block 
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translation of the earliest zygotic transcripts, CRD-
BP granules were still present (Fig. 4Biv), 
suggesting that zygotic RNAs rather than proteins 
are critical for the formation of CRD-BP granules. 
The KH3&4 di-domain is sufficient for CRD-
BP granule formation in zebrafish embryos - To 
determine if the requirement for CRD-BP granule 
formation in zebrafish embryos is similar to that 
previously observed in mouse NIH3T3 embryo 
fibroblast cells (20), we first assessed the deletion 
variants of CRD-BP-EGFP. A schematic diagram 
showing all deletion variants is illustrated in Fig. 
5A and representative results of CRD-BP granule 
formation are shown in Fig. 5B. Injection of 
RRM1&2-EGFP or KH1&2-EGFP mRNAs failed 
to result in any granule formation (Fig. 5B and C) 
which is consistent with previous results in 
NIH3T3 cells (20) and in several studies which 
concluded that the RRM domains and KH1&2 
domains alone are insufficient for interaction with 
target RNAs (19-21). Fig. 5B shows that KH1 to 
4-EGFP granule formation is comparable to that of 
the WT CRD-BP-EGFP, and this is further 
confirmed by quantifying the number of granules 
per cell as shown in Fig. 5C. This is in good 
agreement with the previous finding that KH 
domains 1-4 is sufficient to assemble granules (20) 
and bind target RNAs (19, 20). Injection of Di-
KH3&4-EGFP mRNA, but not KH4-EGFP 
mRNA, also resulted in granule formation (Fig. 
5B). Surprisingly, we found a significantly higher 
number of granules per cell in Di-KH3&4-EGFP-
expressed embryos as compared to embryos 
expressing the WT CRD-BP-EGFP (Fig. 5C). This 
result is consistent with findings that KH domains 
3-4 can bind target RNA efficiently (21). 
However, a previous study showed no granule 
formation in NIH3T3 cells upon expressing GFP-
KH3-4, and KH3-4 of IMP1 could not bind H19 
RNA (20). The deviation in granule formation 
results could be due to one or a combination of the 
following: (i) cellular differences between 
zebrafish embryos and NIH3T3 cells, (ii) time 
differences and hence differences in the dynamics 
of CRD-BP-RNA interaction, or (iii) granules are 
less distinguishable in NIH3T3 cells. The 
deviation in RNA binding ability of KH3-4 is most 
likely due to differences in RNA targets used in 
the different studies, as we have observed the 
different contribution of each KH domain of CRD-
BP in binding different RNA molecules (Figs. 2 
and 3; unpublished observation). There was an 
accumulation of Di-KH3&4-EGFP in the nuclei of 
zebrafish embryos, which was not seen with KH1 
to 4-EGFP (Fig. 5B), suggesting that there may be 
a nuclear export signal located within KH domains 
1-2. In support of this hypothesis was the 
observation of a similar nuclear accumulation of 
KH4-EGFP (Fig. 5B). Indeed, Nielsen and 
colleagues have reported that there are IMP1 
nuclear export signals located in KH2 and KH4 
(33).  We also examined the expression of other 
single KH domains, namely KH1-EGFP, KH2-
EGFP and KH3-EGFP, but again no granule 
formation in zebrafish embryos was observed (Fig. 
5B and C). We also noted that KH1-EGFP 
accumulated in the nuclei while KH3-EGFP was 
accumulated in the cytoplasm and KH2-EGFP 
appeared to be evenly distributed throughout the 
nuclei and cytoplasm (Fig. 5B). However, we 
cannot rule out possible differences in cell cycle 
when these images were acquired.  Finally, to 
determine if the granule formation by a 
combination of two KH domains is unique to di-
KH3&4-EGFP, we examined all other possible di-
domain combinations.   Fig. 5B and C show that 
di-KH1&3-EGFP, di-KH1&4-EGFP, di-KH2&3-
EGFP, and di-KH2&4-EGFP did not show any 
distinct granule formation although some of these 
di-domains appeared to be more patchy (Fig. 5B).  
Hence, we conclude that KH3&4 di-domain is the 
minimal region of CRD-BP necessary for granule 
formation. 
Point mutations in the GXXG motif in two KH 
domains generally reduces CRD-BP granule 
formation in zebrafish embryos - Having shown 
that CRD-BP granule formation in zebrafish 
embryos indeed correlated with the known RNA-
binding ability amongst CRD-BP deletion 
variants, we next investigated the role of each KH 
domain in CRD-BP granule formation in zebrafish 
embryos in the context of the full length mutant 
proteins. To do this, we generated pSp64TNE-
CRD-BP plasmid constructs containing the point 
mutation in the GXXG motif of each of the 
individual KH domain of CRD-BP. The KH 
domain point mutation variants generated were 
those used in the EMSA studies described earlier 
(Figs. 2 and 3). As shown in Fig. 6A, granule 
formation for the single point mutants was 
indistinguishable from that of the WT CRD-BP. 
Results corresponding to CRD-BP granule 
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formation for the KH domain double mutants are 
shown in Fig. 6A and the quantitative data are 
shown in Fig. 6B. Interestingly, KH3-4 was the 
only double mutant that exhibited comparable 
granule formation to the WT CRD-BP (Fig. 6A 
and B). Granule formation was significantly 
reduced when zebrafish embryos were injected 
with KH1-3-EGFP, KH1-4-EGFP, KH2-3-EGFP 
or KH2-4-EGFP mRNAs (Fig. 6A and B). 
Granule formation with KH1-2 was also reduced 
although did not reach statistically significant 
levels (Fig. 6A and B). In summary, we observed 
that the CRD-BP granule formation in zebrafish 
embryos by the KH point mutation variants 
correlated remarkably with their ability to bind c-
myc and CD44 RNA in vitro (Table 1). 
 
A point mutation at the GXXG motif in KH 
domains generally reduces the ability of CRD-BP 
to associate with c-myc and CD44 mRNAs in 
HeLa cells - Next, we were interested in 
determining whether the point mutations in the 
GXXG motif of the KH domains had any effect on 
the ability of CRD-BP to physically interact with 
CD44 and c-myc mRNAs in mammalian cells. We 
transfected HeLa cells with pcDNA-CRD-BP-
FLAG plasmids containing the point mutations as 
described in Fig. 1A. The pcDNA-FLAG and 
pcDNA-CRD-BP-FLAG plasmids containing 
Y5A, D526E, Q84A or E445D mutations were 
used as negative controls. No genomic DNA 
contamination was observed in the immuno-
precipitated RNA samples. This was indicated by 
a lack of PCR product amplified in the no-RT 
qPCR reactions (data not shown).  
As shown in Fig. 7A, with the exception of 
E445D and Q84A variants, equal amounts of 
FLAG-CRD-BP were immuno-precipitated from 
cells transfected with different CRD-BP variants 
with single or double point mutations.  All 
expressed FLAG-CRD-BP at approximately equal 
amounts based on similar volumes of cell lysate 
used for immunoprecipitation. The equal 
Integrated Density Values obtained from 
quantification using the AlphaEaseFC software 
program confirmed this observation.  The reason 
for the lack of FLAG-CRD-BP detected in the 
Q84A and E445D variants is unknown, but could 
possibly be the result of a masked FLAG-tag as a 
consequence of structural changes. Using equal 
amounts of immuno-precipitated proteins, we 
measured CD44, c-myc and β–actin mRNAs that 
were physically associated with FLAG-CRD-BP 
(Fig. 7B). As shown, the level of all three 
transcripts associated with FLAG-CRD-BP in 
cells transfected with Y5A and D526E variants 
were similar to those in WT CRD-BP.  In contrast, 
the level of CD44 mRNA associated with FLAG-
CRD-BP was significantly reduced in cells 
transfected with any of the KH domain point 
mutation variants.  Similarly, with the exception of 
the KH4 variant, the amount of c-myc mRNA 
associated with FLAG-CRD-BP was also 
significantly reduced in cells transfected with KH 
variants. On the contrary, the level of β–actin 
mRNA physically associated with FLAG-CRD-BP 
in the WT CRD-BP- and KH mutant-transfected 
cells were very similar except for the KH3, KH1-
4, and KH2-4 variants. In summary, we conclude 
that the GXXG mutants generally retarded the 
ability of CRD-BP to bind CD44 and c-myc 
mRNAs in HeLa cells. The results also suggested 
that as observed in vitro, there is a differential 
contribution of the CRD-BP KH domains to 
binding its various mRNA targets in HeLa cells. 
 
DISCUSSION 
A number of animal studies have now 
confirmed the critical role played by CRD-BP 
during embryogenesis and tumorigenesis (18,34-
37), but unfortunately the exact molecular 
mechanism of this onco-fetal protein is still 
unclear. However, cumulative evidence from 
studies in vitro and in cell lines suggests that the 
ability to physically interact with a subset of 
mRNAs play a significant part in the function of 
CRD-BP and its orthologs. Hence, it is of the 
utmost importance to clearly understand how 
CRD-BP interacts with its RNA substrates. To 
date, in vitro and granule formation studies in 
mammalian cells using CRD-BP orthologs have 
shown that the KH domains, and not the RRM 
domains, are directly involved in binding RNA 
substrates (19,20). However, the extent to which 
each of the KH domains of CRD-BP contributes to 
the physical interaction with RNA is less clear. 
This is partly because most of the studies were 
based on deletion analysis. The RNA binding 
function of the KH domains for a number proteins 
have been shown to be severely impeded upon 
mutating the first glycine in the GXXG motif to an 
aspartate (24-27). Using a similar approach, we 
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investigated the role of each of the KH domains in 
the context of the full-length protein in binding c-
myc and CD44 RNAs in vitro and in cells, in 
addition to granule formation in intact zebrafish 
embryos. 
Using electrophoretic mobility gel-shift 
assays, we found that a single point mutation in 
the GXXG motif at each of the four KH domains 
generally had no impact on the ability of CRD-BP 
to bind c-myc and CD44 RNAs (Figs. 2 and 3). 
The only exception to this was an inefficient 
binding of the KH4 variant to CD44 RNA. 
However, point mutations in the GXXG motif of 
any combination of two KH domains, with the 
exception of the simultaneous mutation at both 
KH3 and KH4 domains (KH3-4), resulted in 
complete abrogation of RNA binding (Figs. 2 and 
3). CD spectral analysis showed no global 
secondary structural changes for the mutant 
proteins. This is also consistent with a recent 
finding that the GXXG-to-GDDG mutation in the 
four KH domains of KSRP as well as in the KH3 
and KH4 domains of ZBP1 did not destabilize the 
KH domains (28). However, we do not rule out the 
possibility of local structural changes in the KH 
domains of the point mutants, which cannot be 
detected using CD spectroscopy. This may explain 
why the KH4 single mutant has significantly 
reduced binding while the KH3-4 double mutant 
binds CD44 RNA efficiently. It is possible that for 
this specific double mutant, local structural 
changes at regions outside the GXXG motif within 
KH3 and KH4 facilitate binding to CD44 RNA. 
Further structural experiments that are beyond the 
scope of this study are required to resolve this 
apparent anomaly. 
The ability of IMP1 to bind RNA has been 
considered a pre-requisite for the formation of 
IMP1 granules in mammalian cells (20). The 
IMP1 granules are ribonucleoprotein complex that 
are believed to form leading to functional IMP1 
involved in mRNA stability (9) and granule 
localization/transport (20). The granules collected 
from HEK293 human embryonic kidney cells 48 
hours after transfection with plasmid carrying 
FLAG-IMP1 are distinct from stress granules and 
P bodies, and are enriched in mRNAs encoding 
proteins involved in endoplasmic reticulum and 
Golgi function (38). Therefore, we investigated 
whether our in vitro EMSA data with the KH point 
mutants correlates with CRD-BP granule 
formation by the variants. Here, we provide the 
first description of CRD-BP granule formation in 
intact zebrafish embryos and demonstrate that 
CRD-BP granule formation is dependent on 
zygotic mRNAs and not maternal mRNAs (Fig. 
4). The zygotic mRNA dependence of CRD-BP 
granule formation is in-line with the onco-fetal 
role of this protein, which is overexpressed in 
neonatal tissues (39). Also, we find that the ability 
of the various mutant proteins to bind RNA in 
vitro is a good indication for CRD-BP granule 
formation as demonstrated using intact zebrafish 
embryos. Truncated CRD-BP-EGFP, such as 
RRM1&2 and KH1&2, which have been shown to 
have no ability to bind RNA (19,20), could not 
form granules in zebrafish embryos. However, 
KH1to4 CRD-BP-EGFP which binds RNA in 
vitro (19,20), resulted in granule formation that 
was comparable to the WT CRD-BP (Fig. 5). We 
found a significantly greater number of granules 
per cell in embryos expressing the truncated 
KH3&4 CRD-BP-EGFP as compared to the WT 
CRD-BP (Fig. 5C), which is consistent with its 
ability to bind RNA efficiently as previously 
reported (21). Such an effect is unique to the 
KH3&4 di-domains because all of the other 
possible KH di-domain combinations did not show 
granule formation (Fig. 5). On examining the KH 
point mutants for granule formation, we found a 
remarkable correlation between the ability to bind 
c-myc and CD44 RNAs in vitro and CRD-BP 
granule formation in zebrafish embryos. For 
instance, the single point mutants generally did not 
display reduced granule formation or RNA-
binding (Table 2). In contrast, with the exception 
of KH3-4, the KH domain double mutants 
displayed a significant reduction in both granule 
formation and RNA-binding. Based on these 
observations, we propose that at least two KH 
domains of CRD-BP bind to RNA in tandem. This 
is consistent with a recent x-ray crystallography 
study, whereby the individual domains in the 
KH3&4 didomain were shown to be arranged in 
an intramolecular anti-parallel pseudodimer 
conformation, which requires that the bound RNA 
must loop to contact both KH domains 
simultaneously (21). Also, in agreement with the 
previous study is the observation that the KH3&4 
di-domain is important for binding RNA, and that 
sites other than the GXXG motif within the KH3 
and KH4 domains play a critical role in binding 
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RNA substrates. This is because we found that a 
point mutation in the GXXG motif in both the 
KH3 and KH4 domains in combination, had no 
effect on CD44 and c-myc RNA-binding as well as 
granule formation. 
However, based on our point mutation studies, 
we further observe that KH1 and KH2 also play a 
critical role in binding RNA substrates. Our study 
revealed that KH1 and KH2 domains also 
participate with at least another KH domain in 
binding RNA. The role for KH1 and KH2 in 
RNA-binding is also supported by two earlier 
indirect observations: (i) unlike the full-length 
protein, KH3&4 do not associate with RNA below 
100 nM (11), and (ii) the KH1&2 di-domain 
modulates binding of IMP1 to β–actin and c-myc 
RNA in vitro (2). Furthermore, using a filter-
binding assay, significant reduction in RNA-
binding was only observed upon GXXG to GEEG 
mutation in all four KH domains of ZBP1 (40). 
Although there is generally a similar trend in 
binding c-myc and CD44 RNAs by the KH 
variants, there are a few notable deviations. While 
the KH4 variant binds c-myc RNA with a Kd 
similar to that of WT CRD-BP, it did not bind 
CD44 RNA efficiently and hence no Kd can be 
calculated. Similarly, the KH2 and KH3 variants 
bind to CD44 RNA less efficiently than to c-myc 
RNA. These results suggest that indeed CRD-BP 
utilizes distinct KH domains when binding to 
different RNA substrates. 
The investigation into the physical interaction 
between CRD-BP mutants with c-myc, CD44 and 
β-actin mRNAs using immuno-precipitation (IP) 
coupled with the qPCR method, yielded somewhat 
surprising results. Consistent with the in vitro 
EMSA and CRD-BP granule formation results, 
significant reduction in both c-myc and CD44 
mRNAs, but not the β–actin mRNA, were found 
associated with the KH domain double mutants. 
Unexpectedly, we found that the KH3-4 variant 
also had a significantly reduced amount of CD44 
and c-myc mRNAs physically associated with it. 
Similarly, a single point mutation in just one KH 
domain, significantly reduced the level of CD44 
and c-myc mRNAs binding to it, with the 
exception of the KH4 variant, which was still able 
to bind c-myc mRNA. We reasoned that the 
biochemical method employed in this study is 
valid because Y5A and D526E variants which 
bind RNA as effectively as the WT CRD-BP in 
vitro (Figs. 2 and 3) had levels of c-myc and CD44 
mRNAs comparable to that of WT CRD-BP in the 
immuno-precipitation experiments. Furthermore, 
except for KH1-4, KH2-4 and KH3 variants, there 
was no significant reduction in the amount of β-
actin mRNA associated with all the other KH 
variants. The surprising results with KH3-4 and 
the single point mutants which were different from 
the in vitro EMSA and granule formation results 
may be potentially explained by the following: 
CRD-BP is known to associate with various RNA-
binding proteins and mRNAs in ribonucleoprotein 
complexes (9,38). Hence, it is not unexpected to 
find differences in the dynamics of CRD-BP-RNA 
interactions 48 hours after transfection as 
performed in the HeLa cells experiments as 
opposed to the direct in vitro EMSA and in the 
granule formation experiments in zebrafish which 
occurred 4 hours after injection of mRNAs (Table 
2). Such a proposal is supported by an earlier 
report of the lack of granule formation in NIHT3 
cells 48 hours after transfection with the KH3&4-
GFP didomain (20). The immuno-precipitation 
experiments also revealed the following novel 
findings: (i) different mRNAs bind to CRD-BP 
mutants variably in cells as exemplified by the 
interaction of c-myc mRNA with the KH4 variant 
and β–actin mRNA binding to the KH3, KH1-4 
and KH2-4 variants, and (ii) the individual KH 
domains play an important role in the physical 
interaction between CRD-BP and specific mRNA 
in cells. Indeed, our data supports an earlier 
proposal that individual KH domains may have 
distinct functions. This was based on multiple 
sequence alignment analyses of CRD-BP and its 
orthologs, which indicates a higher degree of 
amino acid sequence similarity between the 
equivalent KH domains from different proteins 
than between KH domains within the same protein 
(19). 
Understanding the RNA sequences and/or 
structures that are recognized by CRD-BP is 
important to uncovering its cellular function. 
Consensus primary RNA sequences have been 
identified using various methods, and were 
proposed to be targets of IMP1 or ZBP1. Using the 
SELEX method, the consensus sequence 5’-
ACACCC-3’, was found in RNAs bound to the 
full-length ZBP1 as well as to the truncated KH3-4 
domains of ZBP1 (41). Using the immuno-
precipitation method coupled with microarray 
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analysis, it was found that 307 transcripts 
associated with IMP1 granules were enriched in 
CCYHHCC (where Y = C or U and H = C, U or 
A) motif (38). More recently, the PAR-CLIP 
method was used to assess RNA-binding protein 
recognition elements for FLAG/HA-tagged IMP1, 
IMP2 and IMP3 (42). An RNA recognition 
element CAUH (H = A, U or C) was found in 
more than 75% of the top 1000 clusters from 
100,000 sequence clusters recognized by the IMPs 
(43). Interestingly, our initial analysis of the 
secondary structure of the regions of c-myc (43) 
and CD44 (44) RNA that bind with high affinity to 
CRD-BP showed that sequences located in single-
stranded regions have some potential overlap with 
the previously reported consensus sequences 
recognized by IMP1/ZBP1. For instance, 5’-
AAACA-3’ at nts 20-24, 5’-ACAG-3’ at nts 63-
66, and 5’-ACA-3’ at nts 70-72 are located in 
single-stranded regions of c-myc RNA and contain 
a partial match to the consensus sequence 
ACACCC. Similarly, 5’-CCCAAUU-3’ is located 
at nts 11-17 in a single-stranded region of CD44 
RNA and is close to matching the consensus 
sequence CAUH. This shows that there is no strict 
‘consensus’ sequence for binding RNA and 
suggests that secondary and tertiary structural 
elements are likely key for interaction. Therefore, 
further in-silico analysis of structural elements 
within target RNAs and crystallographic studies 
on the CRD-BP-RNA complex are required to 
fully elucidate the factors governing molecular 
recognition.  
Using site-directed mutagenesis in the context 
of the entire protein, this study shows for the first 
time that at least two KH domains of CRD-BP act 
in tandem for efficient binding to two oncogenic 
mRNAs, c-myc and CD44, as well as for early 
RNP granule formation in zebrafish embryos. 
These results show that in vitro EMSA is indeed a 
valid method for assessing specific CRD-BP-RNA 
interactions that is translatable to an in vivo 
system, as shown for RNP granule formation in 
zebrafish embryos. This study supports the notion 
that mutating the GXXG motif within the KH 
domains (28) is a powerful tool for investigation 
into the function of individual KH domains in 
RNA-binding proteins. We show that mutating the 
first glycine to an aspartate in the GXXG motif is 
sufficient for such purposes.  We also show for the 
first time that each KH domains is required for 
binding c-myc and CD44 mRNAs at the later stage 
of RNP formation as observed in the HeLa cells. 
Based on our overall data, we propose that the 
dynamics of the CRD-BP-mRNA interaction vary 
over time in-vivo. This study has important 
implications for our understanding of the 
oncogenic mechanism of CRD-BP as well as in 
the future design of inhibitors targeted against 
CRD-BP function. 
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FIGURE LEGENDS 
 
FIGURE 1.  Generation of wild type CRD-BP and CRD-BP point mutation variants.  A,Schematic 
representation of the mouse CRD-BP and its variants used in the gel-shift experiments described in 
Figures 2 and 3. The two RRM and four KH domains are shown. As shown, the first Gly of the GXXG 
motif of the KH domain was mutated to an aspartate. Single (KH1, KH2, KH3, KH4) or double (KH1-2, 
KH1-3, KH1-4, KH2-3, KH2-4, KH3-4) point mutation was performed to generate the KH CRD-BP 
variants. Single point mutation was performed to generate the Y5A, Q84A, E445D and D526E variants. B, 
Purification of recombinant His-tagged wild-type CRD-BP and its point mutation variants. Two µg of 
purified recombinant wild-type (WT) CRD-BP and its variants were run on a 12% SDS-PAGE followed 
by staining with Coomassie brilliant blue. 
 
FIGURE 2. The binding profile of CRD-BP and its point mutation variants on the coding region 
determinant of c-myc RNA. A, Electrophoretic mobility gel-shift assay on the binding of purified 
recombinant WT CRD-BP and its point mutation variants to [
32
P] c-myc CRD RNA nts 1705-1886. 
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Various concentrations of proteins, as indicated, were incubated with 40 nM of the radiolabeled c-myc 
RNA. The positions of protein-RNA complexes (Bound) and unbound RNA (Unbound) are indicated. 
Samples within each panel indicate the same experiment. B, A summary of dissociation constants (Kd) of 
the WT CD-BP and its variants. The Kd values were taken from saturation binding curves (n = 4). The 
asterisk indicates that the p-value is less than 0.05 based on Student’s t-test in comparing to the Kd of WT 
CRD-BP. For KH3-4 the P = 0.0321, and for KH1 the P = 0.0122. 
 
FIGURE 3. The binding profile of CRD-BP and its point mutation variants on a specific 3’ untranslated 
region of CD44 RNA. A, Electrophoretic mobility gel-shift assay on the binding of purified recombinant 
WT CRD-BP and its point mutation variants to [
32
P] CD44 RNA nts 2862-3055. Various concentrations 
of proteins, as indicated, were incubated with 40 nM of the radiolabeled CD44 RNA. The positions of 
protein-RNA complexes (Bound) and unbound RNA (Unbound) are indicated. Samples within each panel 
indicate the same experiment with the exception of the panel showing WT and KH3-4. B, A summary of 
dissociation constants (Kd) of the WT CD-BP and its variants. The Kd values were taken from saturation 
binding curves (n = 4). The asterisk indicates that the p-value is less than 0.05 based on Student’s t-test in 
comparing to the Kd of WT CRD-BP. P = 0.0371 for Y5A, P = 0.005 for D526E, P = 0.0121 for KH1, P = 
0.0091 for KH2, and P = 0.0143 for KH3. 
 
FIGURE 4. CRD-BP granule formation in zebrafish embryos. A, Granule formation coincides with 
maternal zygotic transcription. Embryos were injected with mouse CRD-BP-EGFP mRNA at the one-cell 
stage and then imaged at 3 hpf (i) or 4 hpf (ii). For comparison, the human IMP1-EGFP mRNA was 
injected and imaged at 4 hpf (iii). B, Effect of transcriptional inhibitor or protein synthesis inhibitor on 
CRD-BP granule formation. After injection with CRD-BP-EGFP mRNA at the one-cell stage, the 
embryos were injected with actinomycin D (Act D) (20 µg/ml) immediately (ii). Some embryos were 
injected with cycloheximide (CHX) (20 µg/ml) immediately (iii) or at 16-cell stage (iv). Embryos were 
then imaged at 4 hours post-fertilization to examine the effect of drug treatment on CRD-BP granule 
formation. Data shown are representatives of three biological replicates. Scale = 10 µm.  
 
FIGURE 5. Comparing truncated CRD-BP variants on granule formation in zebrafish embryos. A, 
Schematic representation of the mouse CRD-BP and its truncated variants used in this study.  B, Embryos 
were injected with the WT CRD-BP-EGFP or various truncated variant mRNAs as shown at the one-cell 
stage. Embryos were then imaged at 4 hpf. Data shown are representatives of three biological replicates. 
Scale = 10 µm. C, The number of granules per cell were counted as described in Experimental Procedures 
and expressed as shown in the bar graph. At least three images per sample were counted from two separate 
mRNA injections. One-way ANOVA was performed as statistical analysis. The asterisk indicates p < 0.01 
when compared with the WT CRD-BP. 
 
FIGURE 6. Comparing CRD-BP point mutation variants on granule formation in zebrafish embryos. A, 
Embryos were injected with mRNA for the single KH point mutation CRD-BP, KH double point mutation 
CRD-BP, or WT CRD-BP-EGFP as shown at the one-cell stage. Embryos were then imaged at 4 hpf. Data 
shown are representatives of three biological replicates. Scale = 10 µm. B, The number of granules per cell 
were counted as described in the Experimental Procedures. At least three images per sample were counted 
from three separate mRNA injections. One-way ANOVA was performed as statistical analysis. The 
asterisk indicates p < 0.05 when compared with the WT CRD-BP. 
 
FIGURE 7. Comparing mRNA levels that are physically associated with CRD-BP and its point mutation 
variants in HeLa cells. HeLa cells were transfected with plasmid vector pcDNA3-FLAG, pcDNA3-FLAG 
WT CRD-BP, or various pcDNA3-FLAG plasmids carrying CRD-BP variants as shown. Forty-eight 
hours after transfection, lysates from cells were isolated and subjected to immuno-precipitation using anti-
FLAG antibody as described in the Experimental Procedures. A, Sixteen µl of immuno-precipitated 
FLAG-CRD-BP proteins were subjected to Western analysis using anti-FLAG antibody as shown. The 
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FLAG-CRD-BP bands from each transfection were quantified as Integrated Density Value (IDV) and 
expressed relative to the WT CRD-BP.  B, RNAs that were physically associated with pulled down 
FLAG-CRD-BP were extracted and subjected to qRT-PCR for measurements of CD44, c-myc and β–actin 
mRNAs. mRNA levels were expressed relative to the pcDNA3-FLAG vector. The data collected from 
four biological replicates were then pooled and expressed relative to the WT CRD-BP which was taken as 
1.0. One-way ANOVA statistical analysis was then performed to compare the single (middle panel) and 
double (right panel) KH variants to the WT CRD-BP: CD44 mRNA/single KH variants, n = 5, F = 21.08, 
*P < 0.0001; CD44 mRNA/double KH variants, n = 7, F = 22.43, *P < 0.0001; c-myc mRNA/single KH 
variants, n = 5, F = 10.36, **P = 0.0003; c-myc mRNA/double KH variants, n = 7, F = 13.01, *P < 0.0001; 
β-actin mRNA/single KH variants, n = 5, F = 0.909, P = 0.4837; β-actin mRNA/double KH variants, n = 
7, F = 1.005, P = 0.4579. 
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TABLES 
 
TABLE 1    
A summary of the dissociation constants (Kd) of WT CRD-BP in comparison with its KH variants for 
binding to c-myc CRD  and CD44 RNAs 
CRD-BP 
variant 
c-myc RNA nts 1705-1886 CD44 RNA nts 2862-3055 
 Dissociation 
constant (Kd) 
Hill coefficient Dissociation 
constant (Kd) 
Hill coefficient 
WT 398.0  ± 52.79 1.768 ± 0.011 149.32 ± 8.42 1.916 ± 0.0080 
KH1 723.1 ± 75.13 1.539 ± 0.004 211.18 ± 34.94 1.824 ± 0.0173 
KH2 360.3 ± 70.41 1.680 ± 0.013 250.27 ± 26.72 1.756 ± 0.0089 
KH3 320.8 ± 42.75 1.790 ± 0.012 219.32 ± 19.35 1.826 ± 0.0090 
KH4 320.4 ± 59.08 1.787 ± 0.017 NA NA 
KH1-2 NA NA NA NA 
KH1-3 NA NA NA NA 
KH1-4 NA NA NA NA 
KH2-3 NA NA NA NA 
KH2-4 NA NA NA NA 
KH3-4 586.9 ± 42.89 1.728 ± 0.004 133.33 ± 11.04 1.849 ± 0.0112 
Y5A 467.6 ± 45.68 1.755 ± 0.007 100.11 ± 16.41 1.978 ± 0.0297 
D526E 402.4 ± 37.25 1.767 ± 0.007 90.65 ± 1.64 1.986 ± 0.0034 
Q84A 490.6±20.01 1.748 ± 0.003 ND ND 
E445D 459.5 ± 42.18 1.751 ± 0.006 ND ND 
NA indicates not applicable because significantly reduced or no binding occurred and hence binding curve 
cannot be plotted. ND indicates not determined. Data are means ± s.e.m. 
 
 
 
 
TABLE 2  
A summary of the electrophoretic mobility shift assay, zebrafish granule formation, and immuno-
precipitation coupled qPCR experiments 
RNA Type of KH 
variants 
In-vitro EMSA
a 
(< 1 hour) 
Granule formation in 
zebrafish embryos
b 
(4 hours) 
mRNA associated 
with FLAG-CRD-BP 
in HeLa cells
c 
(48 hours) 
 
c-myc 
Single KH point 
mutation 
All bind +++ All reduced except 
KH4 
 Double KH point 
mutation 
All no binding 
except KH3-4 
All defect except 
KH3-4 
All reduced 
 
CD44 
Single KH point 
mutation 
All bind except KH4 +++ All reduced 
 Double KH point 
mutation 
All no binding 
except KH3-4 
All defect except 
KH3-4 
All reduced 
a
Taken from Figs. 2 and 3. 
b
Taken from Fig. 6. The granule formation does not focus on specific mRNA species and the row for c-
myc and CD44 is repeated. ‘+++’ indicates normal granule formation compared to WT CRD-BP. 
c
Taken from Fig. 7B. Reduced means mRNA species were found to have reduced level associated with the 
corresponding FLAG-KH variants as compared to its association with the FLAG-WT CRD-BP. 
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